Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy - Tabular View

Tracking Information

First Received Date ^ICMJE

September 14, 2005

Last Updated Date

February 7, 2006

Start Date ^ICMJE

April 2005

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00209131 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy

Official Title ^ICMJE

Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy

Brief Summary

The majority of kidney stones are treated with shock wave lithotripsy (SWL). We are examining if the medication Flomax will result in improved stone passage rates following SWL.

Detailed Description

Placebo blinded study examining the effects of Flomax on stone passage rates following SWL.

Study Phase

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Longitudinal, Defined Population, Prospective Study

Condition ^ICMJE

Urolithiasis

Intervention ^ICMJE

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Enrollment ^ICMJE

Completion Date

September 2005

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

urolithiasis undergoing SWL

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: Kenneth Ogan, MD

404-778-3038

kenneth_ogan@emoryhealthcare.org

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00209131

Responsible Party

Study ID Numbers ^ICMJE

IRB ID: 128-2005

Study Sponsor ^ICMJE

Emory University

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Kenneth Ogan, MD

Emory University

Information Provided By

Emory University

Verification Date

February 2006

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP